NO318623B1 - Prostaglandin-endoperoksid-H-syntase-biosynteseinhibitorer - Google Patents

Prostaglandin-endoperoksid-H-syntase-biosynteseinhibitorer Download PDF

Info

Publication number
NO318623B1
NO318623B1 NO20012061A NO20012061A NO318623B1 NO 318623 B1 NO318623 B1 NO 318623B1 NO 20012061 A NO20012061 A NO 20012061A NO 20012061 A NO20012061 A NO 20012061A NO 318623 B1 NO318623 B1 NO 318623B1
Authority
NO
Norway
Prior art keywords
hydroxy
phenyl
methyl
pyridazinone
methylsulfonyl
Prior art date
Application number
NO20012061A
Other languages
English (en)
Norwegian (no)
Other versions
NO20012061L (no
NO20012061D0 (no
Inventor
Meena V Patel
Lawrence A Black
Anwer Basha
Teodozyj Kolasa
Michael E Kort
Jeffrey J Rohde
Andrew O Stewart
Catherine M Mccarty
Michael J Coghlan
Huaqing Liu
Original Assignee
Abbott Lab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US09/427,768 external-priority patent/US6307047B1/en
Application filed by Abbott Lab filed Critical Abbott Lab
Publication of NO20012061D0 publication Critical patent/NO20012061D0/no
Publication of NO20012061L publication Critical patent/NO20012061L/no
Publication of NO318623B1 publication Critical patent/NO318623B1/no

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/04Centrally acting analgesics, e.g. opioids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D237/00Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
    • C07D237/02Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings
    • C07D237/06Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D237/10Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D237/14Oxygen atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D409/00Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/04Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Immunology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Oncology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Communicable Diseases (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
NO20012061A 1998-10-27 2001-04-26 Prostaglandin-endoperoksid-H-syntase-biosynteseinhibitorer NO318623B1 (no)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US17960598A 1998-10-27 1998-10-27
US26187299A 1999-03-03 1999-03-03
US29849099A 1999-04-23 1999-04-23
US09/427,768 US6307047B1 (en) 1997-08-22 1999-10-27 Prostaglandin endoperoxide H synthase biosynthesis inhibitors
PCT/US1999/025234 WO2000024719A1 (en) 1998-10-27 1999-10-27 Prostaglandin endoperoxide h synthase biosynthesis inhibitors

Publications (3)

Publication Number Publication Date
NO20012061D0 NO20012061D0 (no) 2001-04-26
NO20012061L NO20012061L (no) 2001-06-27
NO318623B1 true NO318623B1 (no) 2005-04-18

Family

ID=27497355

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20012061A NO318623B1 (no) 1998-10-27 2001-04-26 Prostaglandin-endoperoksid-H-syntase-biosynteseinhibitorer

Country Status (19)

Country Link
EP (1) EP1124804B1 (cs)
JP (1) JP2003512292A (cs)
KR (1) KR100666838B1 (cs)
CN (1) CN1279026C (cs)
AT (1) ATE302759T1 (cs)
BG (1) BG65261B1 (cs)
BR (1) BR9914858A (cs)
CA (1) CA2347982A1 (cs)
CZ (1) CZ300570B6 (cs)
DE (1) DE69926903T2 (cs)
DK (1) DK1124804T3 (cs)
ES (1) ES2249919T3 (cs)
HK (1) HK1041876B (cs)
HU (1) HUP0105248A3 (cs)
NO (1) NO318623B1 (cs)
PL (1) PL198503B1 (cs)
SK (1) SK286806B6 (cs)
TR (1) TR200101765T2 (cs)
WO (1) WO2000024719A1 (cs)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2324126T3 (es) 1997-11-19 2009-07-30 Kowa Co., Ltd. Derivados de piridazina y medicamentos que los contienen como ingrediente activo.
TWI241295B (en) 1998-03-02 2005-10-11 Kowa Co Pyridazine derivative and medicine containing the same as effect component
JP2000247959A (ja) 1999-02-26 2000-09-12 Kowa Co ピリダジン−3−オン誘導体及びこれを含有する医薬
CA2362815A1 (en) 1999-12-08 2001-06-14 Pharmacia Corporation Cyclooxygenase-2 inhibitor compositions having rapid onset of therapeutic effect
US6664256B1 (en) 2000-07-10 2003-12-16 Kowa Co., Ltd. Phenylpyridazine compounds and medicines containing the same
US6716829B2 (en) 2000-07-27 2004-04-06 Pharmacia Corporation Aldosterone antagonist and cyclooxygenase-2 inhibitor combination therapy to prevent or treat inflammation-related cardiovascular disorders
AR031129A1 (es) 2000-09-15 2003-09-10 Pharmacia Corp Derivados de los acidos 2-amino-2-alquil-4-hexenoico y -hexinoico utiles como inhibidores de oxido nitrico sintetasa
MY131964A (en) 2000-09-15 2007-09-28 Pharmacia Corp 2-amino-2-alkyl-5 heptenoic and heptynoic acid derivatives useful as nitric oxide synthase inhibitors
US7012098B2 (en) 2001-03-23 2006-03-14 Pharmacia Corporation Inhibitors of inducible nitric oxide synthase for chemoprevention and treatment of cancers
DE10129320A1 (de) 2001-06-19 2003-04-10 Norbert Mueller Verwendung von COX-2 Inhibitoren zur Behandlung von Schizophrenie, wahnhaften Störungen, affektiven Störungen oder Ticstörungen
GEP20063937B (en) 2002-02-14 2006-10-10 Pharmacia Corp Substituted pyridinones as modulators of p38 map kinase
JP2006511606A (ja) 2002-12-13 2006-04-06 ワーナー−ランバート・カンパニー、リミテッド、ライアビリティ、カンパニー 下部尿路症状を治療するα−2−δリガンド
US20040204411A1 (en) * 2002-12-17 2004-10-14 Pharmacia Corporation Method for the treatment, prevention, or inhibition of a CNS disorder and/or pain and inflammation using a combination of reboxetine and a cyclooxygenase-2 selective inhibitor and compositions thereof
ES2211344B1 (es) * 2002-12-26 2005-10-01 Almirall Prodesfarma, S.A. Nuevos derivados de piridazin-3(2h)-ona.
KR20050113627A (ko) 2003-03-18 2005-12-02 코와 가부시키가이샤 수용성 페닐피리다진 유도체 및 이를 함유하는 의약
JP4354984B2 (ja) 2003-05-07 2009-10-28 オステオロジックス エイ/エス 水溶性ストロンチウム塩を用いる軟骨/骨症状の治療
ES2251866B1 (es) 2004-06-18 2007-06-16 Laboratorios Almirall S.A. Nuevos derivados de piridazin-3(2h)-ona.
US7728031B2 (en) 2006-02-24 2010-06-01 Abbott Laboratories Octahydro-pyrrolo[3,4-b]pyrrole derivatives
EP1916240A1 (en) * 2006-10-25 2008-04-30 Syngeta Participations AG Pyridazine derivatives
KR20090092307A (ko) 2006-12-22 2009-08-31 레코르다티 아일랜드 리미티드 하요도 장애에 대한 α2δ 리간드 및 NSAIDs의 복합 치료
DE102007008839A1 (de) * 2007-02-23 2008-08-28 Bayer Healthcare Ag Verfahren zur Herstellung von 4-(3-Hydroxy-3-methyl-butoxy)-5-[4-(methylsulfonyl)phenyl]-2-arylpyridazin-3(2H)-onen
DE102007008840A1 (de) * 2007-02-23 2008-08-28 Bayer Healthcare Ag Neue polymorphe Form von 2-(4-Fluorophenyl)-4-3-hydroxy-3-methyl-1-butoxy)-5-[4-methylsulfonyl)phenyl]-3(2H)-pyridazinon (FHMP)
DE102007008843A1 (de) 2007-02-23 2008-08-28 Bayer Healthcare Ag Verfahren zur Herstellung von 4,5-Dihalogen-2-aryl-2H-pyridazin-3-onen
DE102007020690A1 (de) * 2007-05-03 2008-11-06 Bayer Healthcare Ag Neue amorphe Form von 2-(4-Fluorophenyl)-4-3-hydroxy-3-mehtyl-1-butoxy)-6[4-methylsulfonyl)phenyl]-3(2H)-pyridazinon (FHMP)
DE102007020689A1 (de) * 2007-05-03 2008-11-06 Bayer Healthcare Ag Neue polymorphe Form von 2-(4-Fluorophenyl)-4-3-hydroxy-3-methyl-1-butoxy-5-[4-methylsulfonyl)phenyl]3/2H)-pyridazinon (FHMP)
DE102007025717A1 (de) * 2007-06-01 2008-12-11 Merck Patent Gmbh Arylether-pyridazinonderivate
GB0716414D0 (en) * 2007-08-22 2007-10-03 Syngenta Participations Ag Novel insecticides
EP2188288A1 (en) 2007-09-11 2010-05-26 Abbott Laboratories Octahydro-pyrrolo[3,4-b]pyrrole n-oxides
GB0903493D0 (en) 2009-02-27 2009-04-08 Vantia Ltd New compounds
JP2012131708A (ja) * 2009-04-28 2012-07-12 Nissan Chem Ind Ltd 4位置換ピリダジノン化合物及びp2x7受容体阻害剤
FR2969606B1 (fr) * 2010-12-22 2013-01-11 Pf Medicament Derives de diarylpyridazinones, leur preparation et leur application en therapeutique humaine
JO3115B1 (ar) 2011-08-22 2017-09-20 Takeda Pharmaceuticals Co مركبات بيريدازينون واستخدامها كمثبطات daao
WO2018049008A1 (en) 2016-09-07 2018-03-15 Trustees Of Tufts College Dash inhibitors, and uses related thereto
CN107334767B (zh) * 2017-06-08 2019-03-05 中国医学科学院医药生物技术研究所 一种哒嗪酮类化合物在肿瘤治疗中的应用
WO2021124344A1 (en) * 2019-12-18 2021-06-24 Abida Pyridazine derivatives and their use as cyclooxygenase-2 inhibitors

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4238490A (en) * 1979-02-12 1980-12-09 Diamond Shamrock Corporation Antihypertensive pyridazin(2H)-3-ones
WO1982000402A1 (en) * 1980-08-07 1982-02-18 Shamrock Corp Diamond Herbicidal and plant growth regulant diphenylpyridazinones
US5622948A (en) * 1994-12-01 1997-04-22 Syntex (U.S.A.) Inc. Pyrrole pyridazine and pyridazinone anti-inflammatory agents
WO1996041645A1 (en) * 1995-06-12 1996-12-27 G.D. Searle & Co. Combination of a cyclooxygenase-2 inhibitor and a leukotriene b4 receptor antagonist for the treatment of inflammations
CA2283399C (en) * 1997-03-14 2006-02-21 Merck Frosst Canada & Co. Pyridazinones as inhibitors of cyclooxygenase-2
WO1999010332A1 (en) * 1997-08-22 1999-03-04 Abbott Laboratories Prostaglandin endoperoxide h synthase biosynthesis inhibitors
HUP0400909A3 (en) * 1997-08-22 2004-10-28 Abbott Lab Arylpyridazinone-derivatives having prostaglandin endoperoxide h synthase biosynthesis inhibitor effect and pharmaceutical compositions containing them
EP1007515A1 (en) * 1997-08-22 2000-06-14 Abbott Laboratories Arylpyridazinones as prostaglandin endoperoxide h synthase biosynthesis inhibitors

Also Published As

Publication number Publication date
SK286806B6 (sk) 2009-05-07
HUP0105248A3 (en) 2002-09-30
BR9914858A (pt) 2002-02-05
BG65261B1 (bg) 2007-10-31
SK5542001A3 (en) 2001-12-03
HK1041876B (en) 2006-06-23
TR200101765T2 (tr) 2002-02-21
PL198503B1 (pl) 2008-06-30
EP1124804B1 (en) 2005-08-24
DE69926903T2 (de) 2006-07-13
KR20010081101A (ko) 2001-08-27
NO20012061L (no) 2001-06-27
ES2249919T3 (es) 2006-04-01
CN1279026C (zh) 2006-10-11
HUP0105248A2 (hu) 2002-07-29
DK1124804T3 (da) 2005-12-12
CA2347982A1 (en) 2000-05-04
EP1124804A1 (en) 2001-08-22
CN1342149A (zh) 2002-03-27
KR100666838B1 (ko) 2007-01-11
HK1041876A1 (en) 2002-07-26
DE69926903D1 (en) 2005-09-29
CZ300570B6 (cs) 2009-06-17
CZ20011481A3 (cs) 2001-09-12
JP2003512292A (ja) 2003-04-02
NO20012061D0 (no) 2001-04-26
BG105523A (en) 2001-12-29
ATE302759T1 (de) 2005-09-15
WO2000024719A1 (en) 2000-05-04
PL349256A1 (en) 2002-07-01

Similar Documents

Publication Publication Date Title
NO318623B1 (no) Prostaglandin-endoperoksid-H-syntase-biosynteseinhibitorer
CA2299300C (en) Arylpyridazinones as prostaglandin endoperoxide h synthase bisoynthesis inhibitors
US6307047B1 (en) Prostaglandin endoperoxide H synthase biosynthesis inhibitors
CA2782453C (en) N-linked hydroxamic acid derivatives useful as antibacterial agents
AU2008206441B2 (en) N-substituted glycine derivatives: hydroxylase inhibitors
AU2008247102B2 (en) 2 -pyridine carboxamide derivatives as sodium channel modulators
CA2828337C (en) Fluoro-pyridinone derivatives useful as antibacterial agents
MXPA02002111A (es) Compuestos de sulfonilfenilpirazol utiles como inhibidores de cox-2.
SK282639B6 (sk) (Metylsulfonyl)fenyl-2-(5H)-furanónové deriváty, farmaceutický prostriedok s ich obsahom a ich použitie
KR102083040B1 (ko) 11-베타-하이드록시스테로이드 탈수소효소의 저해제로서 사이클릭 아마이드 유도체 및 이의 용도
EA021025B1 (ru) Соединения, эффективные в качестве ингибиторов ксантиноксидазы, способ их получения и содержащая их фармацевтическая композиция
AU750019B2 (en) Aryl alkanoylpyridazines
SK170599A3 (en) N-hydroxyformamide derivatives as inhibitors of matrix metalloproteinases
AU2003238667B2 (en) 4-(heterocyclyl)-benzenesulfoximine compounds for the treatment of inflammation
US5571825A (en) Method of selectively inhibiting prostaglandin G/H synthase-2
CZ300847B6 (cs) Arylpyridazinony jako inhibitory biosyntézy prostaglandin endoperoxid H synthasy, jejich použití a farmaceutická kompozice s jejich obsahem
AU773237B2 (en) Prostaglandin endoperoxide H synthase biosynthesis inhibitors
JPH054366B2 (cs)
MXPA01004247A (en) Prostaglandin endoperoxide h synthase biosynthesis inhibitors

Legal Events

Date Code Title Description
MM1K Lapsed by not paying the annual fees